Compare AMC ENTERTAINMENT HOLDINGS, INC. (AMC) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AMC ENTERTAINMENT HOLDINGS, INC. vs Viatris Inc — how do they compare? AMC ENTERTAINMENT HOLDINGS, INC. trades at $2.54 (market cap $2.14B), while Viatris Inc trades at $16.12 (market cap $18.69B). The key difference: Viatris Inc is far larger — about 8.7× AMC ENTERTAINMENT HOLDINGS, INC.'s market cap, and Viatris Inc pays the higher dividend (2.95%). Which is the better fit depends on your goals.
| AMC | VTRS | |
|---|---|---|
Market Cap | $2.14B | $18.69B |
Sector | Media | Health |
52-Week High | $3.15 | $17.86 |
52-Week Low | $0.95 | $9.49 |
Enterprise Value | $9.08B | $30.80B |
Dividend Yield | 0.11% | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMC trades at $2.555, up 5.58% today, with a bullish technical signal and recent earnings beats. The company reported record Q2 2026 revenue and EBITDA, driven by strong box office performance and premium screen growth. However, it remains unprofitable with a net income margin of -10.59% and negative shareholder equity of -$1.76 billion as of 2024. Cash flow trends show improvement, with projected positive operating cash flow of $219 million in 2026.
Outlook is mixed; operational recovery and analyst consensus price target of $3.00 offer upside, but high debt and persistent losses pose significant risks. Investor sentiment is buoyed by record-breaking weekends and international expansion, yet volatility from meme-stock status and competitive pressures require caution.
Viatris (VTRS) trades at $16.105, down 1.07% on the day, with a bearish technical signal and mixed fundamentals. Recent Q2 2026 earnings beat estimates with EPS of $0.69 and revenue growth of 5%, but the company posted a net loss of $3.51B in 2025. Positive developments include FDA approval for Gwyn Lo and a raised 2026 outlook, though debt remains elevated at $14.04B long-term.
Outlook is cautious; while operational cash flow is strong at $2.32B and dividends provide income, persistent net losses and high P/E of 236.2 signal overvaluation risks. Analyst consensus leans Hold (61.54%), with upside potential if turnaround gains traction, but investors face headwinds from generic drug pricing pressures and execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AMC ENTERTAINMENT HOLDINGS, INC.
AMC Entertainment Holdings, Inc. operates as a holding company. The Company, through its subsidiaries, provides theatrical exhibition, movie screening, food distribution, online ticket booking, and other related services. AMC Entertainment offers movie theaters worldwide.
Read more on AMC →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
